SEHK:3696Life Sciences
Insilico Medicine Rides ISM8969 Deals And AI Platform To Strong Rally
Insilico Medicine Cayman TopCo (SEHK:3696) is pushing its ISM8969 NLRP3 inhibitor program forward through new co development deals, regulatory clearance and product progress.
The company has signed collaborations with Qilu Pharmaceutical and Hygtia Therapeutics around ISM8969 for central nervous system and inflammatory diseases, with global rights and large contract values attached.
ISM8969 has received US FDA clearance for a Phase I trial in healthy volunteers, targeting conditions that...